Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29698271 | 1.00 | CA2 (0.31) | CA2LPLLIPG | |
| SCHEMBL426850 | 0.79 | — | — | |
| Water SCHEMBL1669028 | 0.77 | — | — | |
| Water SCHEMBL29954949 | 0.77 | — | — | |
| SCHEMBL30788696 | 0.76 | CCR1 (0.40) | CA2LPLLIPG | |
| SCHEMBL489376 | 0.76 | CCR1 (0.40) | CA2LPLLIPG | |
| SCHEMBL14929718 | 0.76 | — | — | |
| SCHEMBL13260555 | 0.76 | ENPP2 (0.30) | — | |
| SCHEMBL29951491 | 0.74 | CA2 (0.32) | CA2LPLLIPG | |
| SCHEMBL29954944 | 0.74 | NPC1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4634190-A1 | NOVEL COMPOUNDS FOR DIAGNOSIS | AC Immune SA (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-12168655-B2 | Apelin receptor agonists and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-17 | — | — | US | disclosed |
| WO-2024232597-A1 | 4-CHROMANONE COMPOUNDS THAT DEGRADE WDR5 AND USES THEREOF | 엘젠테라퓨틱스 주식회사 | 2024-11-14 | — | — | WO | disclosed |
| US-20240336574-A1 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| CN-118359538-A | Isoquinoline compound, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024126840-A1 | NOVEL COMPOUNDS FOR DIAGNOSIS | AC IMMUNE SA (CH) | 2024-06-20 | — | — | WO | disclosed |
| EP-4304585-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-113166151-B | Substituted xanthine derivatives | 勃林格殷格翰国际有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230373978-A1 | HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-7524870-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-2007750-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | EP | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| WO-2007113232-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GYS2, GYS1, GSK3A | CA2 574/4885LPL 616/4885LIPG 896/4885 |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | CA2 4588/4885LPL 3153/4885LIPG 4869/4885 |
| US-12168655-B2 | Apelin receptor agonists and methods of use | APLNR, AP2B1, AP3B1 | CA2 1391/4885LPL 1957/4885LIPG 2235/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | CA2 4475/4885LPL 517/4885LIPG 248/4885 |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | AZI2, NT5C3B, CYP1B1 | CA2 3616/4885LPL 4821/4885LIPG 4641/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | CA2 2730/4885LPL 3851/4885LIPG 2157/4885 |
| US-20230373978-A1 | HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES | F3, ABL1, CFTR | CA2 4323/4885LPL 3950/4885LIPG 4311/4885 |
| US-20240336574-A1 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | P2RX5, HRH4, TRPV1 | CA2 1931/4885LPL 4838/4885LIPG 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.